Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country.
M Sakil SyeedTeerawat NonthasawadsriRichard E NelsonNathorn ChaiyakunaprukSurakit NathisuwanPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
In a developing country where suboptimal anticoagulation control is common, apixaban was the cost-effective alternative to warfarin for patients with both low and intermediate TTR control.